THE EFFECTS OF MAGNESIUM-HYDROXIDE ON THE ABSORPTION AND EFFICACY OF 2 GLIBENCLAMIDE PREPARATIONS

被引:23
作者
NEUVONEN, PJ
KIVISTO, KT
机构
[1] Department of Pharmacology, University of Turku
关键词
GLIBENCLAMIDE; MAGNESIUM HYDROXIDE; ABSORPTION INTERACTIONS; INSULIN; GLUCOSE;
D O I
10.1111/j.1365-2125.1991.tb03884.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 The effect of magnesium hydroxide on the absorption and efficacy of two glibenclamide preparations was investigated in healthy volunteers in two separate studies, using a randomized cross-over design with two phases. 2 A single dose of magnesium hydroxide (850 mg) or water only (150 ml) was given immediately after the ingestion of a micronised (1.75 mg, seven subjects) or a nonmicronised (2.5 mg, six subjects) preparation of glibenclamide. Plasma concentrations of glibenclamide, insulin and glucose were measured. 3 Magnesium hydroxide accelerated (P < 0.05) the absorption of glibenclamide from the micronised preparation to a small extent but the extent of absorption and the insulin and glucose responses were unaltered. 4 Coadministration of magnesium hydroxide with the non-micronised glibenclamide preparation increased the area under the plasma glibenclamide concentration-time curve from 0 to 3 h, five-fold (P < 0.05), the total area three-fold (P < 0.05) and the peak drug concentration three-fold (P < 0.05). The incremental insulin area from 0 to 3 h was increased 35-fold (P < 0.05) and the maximum insulin response 10-fold (P < 0.05) by magnesium hydroxide. 5 Concomitant ingestion of magnesium hydroxide and non-micronised glibenclamide may greatly enhance the absorption and efficacy of glibenclamide. The absorption of micronised glibenclamide appears to be only slightly influenced by magnesium hydroxide.
引用
收藏
页码:215 / 220
页数:6
相关论文
共 19 条
[1]   PHYSIOLOGICAL IMPORTANCE OF DEFICIENCY IN EARLY PRANDIAL INSULIN-SECRETION IN NON-INSULIN-DEPENDENT DIABETES [J].
BRUCE, DG ;
CHISHOLM, DJ ;
STORLIEN, LH ;
KRAEGEN, EW .
DIABETES, 1988, 37 (06) :736-744
[2]   CORRELATIONS BETWEEN INVITRO DISSOLUTION, INVIVO BIOAVAILABILITY AND HYPOGLYCEMIC EFFECT OF ORAL GLIBENCLAMIDE [J].
CHALK, JB ;
PATTERSON, M ;
SMITH, MT ;
EADIE, MJ .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 31 (02) :177-182
[3]   PHARMACOKINETIC AND PHARMACODYNAMIC STUDIES OF GLIBENCLAMIDE IN NONINSULIN DEPENDENT DIABETES-MELLITUS [J].
COPPACK, SW ;
LANT, AF ;
MCINTOSH, CS ;
RODGERS, AV .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 29 (06) :673-684
[4]   HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC DETERMINATION OF GLIPIZIDE IN HUMAN-PLASMA AND URINE [J].
EMILSSON, H .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1987, 421 (02) :319-326
[5]   SULFONYLUREAS AND HYPOGLYCEMIA [J].
FERNER, RE ;
NEIL, HAW .
BRITISH MEDICAL JOURNAL, 1988, 296 (6627) :949-950
[6]  
GERICH JE, 1989, NEW ENGL J MED, V321, P1231
[7]   EFFECTS OF ANTACIDS ON THE CLINICAL PHARMACOKINETICS OF DRUGS - AN UPDATE [J].
GUGLER, R ;
ALLGAYER, H .
CLINICAL PHARMACOKINETICS, 1990, 18 (03) :210-219
[8]   PHARMACODYNAMICS AND PHARMACOKINETICS OF 2 GLIBENCLAMIDE PREPARATIONS IN TYPE-II DIABETES - INTRAINDIVIDUAL DOUBLE-BLIND COMPARISON OF EUGLUCON-5(HB 419) AND EUGLUCON-N(HB 420) [J].
HAUPT, E ;
PUTSCHKY, F ;
ZOLTOBROCKI, M ;
SCHOFFLING, K .
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1984, 109 (06) :210-213
[9]   ANTACID THERAPY AND DRUG KINETICS [J].
HURWITZ, A .
CLINICAL PHARMACOKINETICS, 1977, 2 (04) :269-280
[10]   INTERINDIVIDUAL VARIATION IN THE ABSORPTION OF GLIBENCLAMIDE IN MAN [J].
IKEGAMI, H ;
SHIMA, K ;
TANAKA, A ;
TAHARA, Y ;
HIROTA, M ;
KUMAHARA, Y .
ACTA ENDOCRINOLOGICA, 1986, 111 (04) :528-532